Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ainos Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AIMD
Nasdaq
8731
https://www.ainos.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ainos Inc
Ainos Reports First Quarter 2024 Financial Results
- May 13th, 2024 8:10 pm
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
- May 7th, 2024 12:00 pm
Ainos Full Year 2023 Earnings: US$3.36 loss per share (vs US$5.14 loss in FY 2022)
- Mar 10th, 2024 12:35 pm
Ainos Reports Full Year 2023 Financial Results
- Mar 8th, 2024 8:20 pm
Small-Cap Growth Virtual Investor Conference Presentations Now Available for Online Viewing
- Feb 8th, 2024 1:35 pm
Small-Cap Growth Virtual Investor ConferenceĀ Agenda Announced for February 7th, 2024
- Feb 6th, 2024 2:51 pm
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
- Feb 5th, 2024 2:00 pm
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
- Feb 1st, 2024 1:35 pm
Ainos Announces $1.75 Million Follow-On Funding
- Jan 24th, 2024 2:00 pm
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Jan 2nd, 2024 2:00 pm
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
- Dec 26th, 2023 2:00 pm
Ainos, Inc. Announces Stock Consolidation
- Dec 12th, 2023 1:00 pm
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
- Nov 28th, 2023 1:30 pm
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
- Nov 21st, 2023 1:30 pm
Ainos Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 9:30 pm
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
- Nov 6th, 2023 1:00 pm
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
- Sep 25th, 2023 12:30 pm
With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients
- Sep 19th, 2023 4:26 pm
Ainosā VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
- Sep 18th, 2023 11:00 am
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
- Sep 5th, 2023 11:00 am
Scroll